13.53
-0.18(-1.31%)
Currency In USD
Previous Close | 13.71 |
Open | 13.74 |
Day High | 13.98 |
Day Low | 13.37 |
52-Week High | 18.38 |
52-Week Low | 8.24 |
Volume | 985,943 |
Average Volume | 888,975 |
Market Cap | 881.82M |
PE | -3.61 |
EPS | -3.75 |
Moving Average 50 Days | 14.82 |
Moving Average 200 Days | 12.95 |
Change | -0.18 |
If you invested $1000 in Mineralys Therapeutics, Inc. (MLYS) since IPO date, it would be worth $733.73 as of June 30, 2025 at a share price of $13.53. Whereas If you bought $1000 worth of Mineralys Therapeutics, Inc. (MLYS) shares 0 years ago, it would be worth $1,111.75 as of June 30, 2025 at a share price of $13.53.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Mineralys Therapeutics Announces Journal of the American Medical Association (JAMA) Publication of Pivotal Phase 3 Launch-HTN Trial for Lorundrostat
GlobeNewswire Inc.
11 hours ago
– The Launch-HTN trial is the largest trial of an aldosterone synthase inhibitor completed in participants with uncontrolled or treatment resistant hypertension – – Lorundrostat 50 mg once daily demonstrated clinically meaningful reductions in systol
Mineralys Therapeutics Announces Positive Topline Results from Phase 2 Explore-CKD Trial of Lorundrostat for the Treatment of Hypertension in Subjects with CKD and Albuminuria
GlobeNewswire Inc.
Jun 17, 2025 11:00 AM GMT
– Explore-CKD met its primary endpoint; lorundrostat 25 mg once daily achieved a 9.3 mmHg reduction in systolic blood pressure, and a 7.5 mmHg placebo-adjusted reduction (p=0.0024) at four weeks – – Lorundrostat showed a clinically meaningful reducti
Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension and Cardiovascular Protection (ESH 2025)
GlobeNewswire Inc.
May 24, 2025 8:30 AM GMT
– Largest hypertension trial of an aldosterone synthase inhibitor to date demonstrated the efficacy of lorundrostat in over 1,000 participants with uncontrolled or resistant hypertension in a real-world setting – – Lorundrostat 50 mg dosed once daily